Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 1/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922153 | 1.00 | ABAT (0.61) | ABATEGLN1POLBTDP1CYP2C19 | |
| SCHEMBL2184769 | 1.00 | ABAT (0.61) | ABATEGLN1POLBTDP1CYP2C19 | |
| SCHEMBL10004987 | 1.00 | ABAT (0.61) | ABATEGLN1POLBTDP1CYP2C19 | |
| SCHEMBL2183908 | 1.00 | ABAT (0.61) | ABATEGLN1POLBTDP1CYP2C19 | |
| SCHEMBL17148774 | 0.80 | ABAT (0.39) | ABAT | |
| SCHEMBL17148769 | 0.80 | ABAT (0.39) | ABAT | |
| SCHEMBL12491864 | 0.78 | ABAT (0.60) | ABATPOLBTDP1CYP2C19GABRR1 | |
| SCHEMBL991477 | 0.77 | ABAT (0.61) | ABATEGLN1POLBTDP1CYP2C19 | |
| SCHEMBL17694222 | 0.77 | ABAT (0.46) | ABATPOLBTDP1CYP2C19GABRP | |
| SCHEMBL23145224 | 0.76 | ABAT (1.00) | ABATEGLN1POLBTDP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110970-A1 | MACROCYCLIC BTK INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| EP-2471797-B1 | 17-DESMETHYLRAPAMYCIN AND ANALOGUES THEREOF, METHODS FOR THEIR PRODUCTION AND THEIR USE AS IMMUNOSUPRESSANTS, ANTICANCER AGENTS, ANTIFUNGAL AGENTS ETC. | BUCK INST FOR RES ON AGING (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2471797-A2 | 17-Desmethylrapamycin and analogues thereof, methods for their production and their use as immunosupressants, anticancer agents, antifungal agents etc. | Biotica Technology Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-7803808-B2 | Production of polyketides and other natural products | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090253732-A1 | Production Of Polyketides And Other Natural Products | BIOTICA TECHNOLOGY LIMITED | 2009-10-08 | — | — | US | disclosed |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253732-A1 | Production Of Polyketides And Other Natural Products | PBK, IL15, IL17A | ABAT 1106/4885EGLN1 1901/4885POLB 2785/4885 |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | CES1, COASY, CYP51A1 | ABAT 531/4885EGLN1 952/4885POLB 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.